RAP charting, page-8366

Agree here @Saragian.
Hands up who thinks they’ve run the machine learning algo a ‘million’ times through the available dataset of kids as increasing numbers of patients have presented to JHC or PMH since ResApp’s last paediatric update in March 2016..

Why - Fine tuning before its officially submitted to FDA for running through the US paediatric trial dataset?

They’re at the crux of company making (or breaking) news. So what is the likelihood that Aus paediatric results stated to be released as a pivotal milestone this quarter are significantly lower now than they were a year ago, with double the number of patients through the machine learning algo?

March 2016 524 patient dataset (85%+ accuracy); 30 May 2017 ASX preso +1100 child patients continuing.

Or looking at it a different way…. As part of the clinical study approvals at each institution, the Australian study has most likely required safety monitoring throughout. That is - if the ongoing trial has (at any time) posed significant risks to patients then surely, we would have had an adverse event, or trial halt update by now. (ie With rates of accuracy/safety significantly lower than first results published, and patients wrongly diagnosed.)

Instead, the May 2017 ASX preso listed both adult and paediatric Australian studies as continuing, with more than 2600+ patients in total.

Remarkable performance by management and the scientific team for a trial cohort made up of the sickest patients attending an hospital’s Emergency Department.

My guess – it’s all ticking along as anticipated ..